Roche and Eli Lilly won U.S. FDA clearance for the Elecsys pTau217 Plasma blood test, enabling clinicians to rule in and rule out Alzheimer’s disease in adults 55 and older presenting with cognitive decline. The assay targets phosphorylated tau (pTau217), linked to amyloid plaque pathology, and is designed for use with Roche’s Cobas lab instruments. The clearance comes as the Alzheimer’s blood-testing landscape heats up: Labcorp and Quest said they plan to offer the test, and the FDA has cleared other pTau and amyloid-related assays earlier in 2025 and 2026. Roche said the pTau217 test uses validated clinical cutoffs to support consistent implementation across primary care and specialty settings. Analysts noted in client commentary that the launch signals rising competition as multiple assays try to drive broader adoption beyond PET imaging and cerebrospinal fluid testing. Labcorp expects nationwide availability in coming months, which could expand diagnostic access in routine care settings. The Elecsys pTau217 Plasma test strengthens a biomarker-led approach to Alzheimer’s staging, positioning blood assays as scalable triage tools prior to confirmatory evaluation.